How to manage Cushing's disease after failed primary pituitary surgery.


Journal

European journal of endocrinology
ISSN: 1479-683X
Titre abrégé: Eur J Endocrinol
Pays: England
ID NLM: 9423848

Informations de publication

Date de publication:
14 Sep 2024
Historique:
received: 03 05 2024
revised: 10 07 2024
accepted: 12 09 2024
medline: 15 9 2024
pubmed: 15 9 2024
entrez: 14 9 2024
Statut: aheadofprint

Résumé

The first-line treatment for Cushing's disease is transsphenoidal adenomectomy, which can be curative in a significant number of patients. Second-line options in cases of failed primary pituitary surgery include repeat surgery, medical therapy and radiation. The role for medical therapy has expanded in the last decade, and options include pituitary-targeting drugs, steroid synthesis inhibitors and glucocorticoid receptor antagonists. Bilateral adrenalectomy is a more aggressive approach, which may be necessary in cases of persistent hypercortisolism despite surgery, medical treatment or radiation or when rapid normalization of cortisol is needed. We review the available treatment options for Cushing's disease, focusing on the second-line treatment options to consider after failed primary pituitary surgery.

Identifiants

pubmed: 39276376
pii: 7758155
doi: 10.1093/ejendo/lvae110
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

Auteurs

Nidhi Agrawal (N)

Division of Endocrinology, Diabetes and Metabolism, New York University Langone Medical Center, New York, NY, USA.

Sandrine A Urwyler (SA)

Clinic of Endocrinology, Diabetes and Metabolism, Department of Clinical Research, University Hospital Basel, Basel, Switzerland.

Sonal Mehta (S)

Division of Endocrinology, Diabetes and Metabolism, New York University Langone Medical Center, New York, NY, USA.

Niki Karavitaki (N)

Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK; Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, UK; Department of Endocrinology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.

Richard A Feelders (RA)

Department of Internal Medicine, Erasmus MC, Rotterdam, Netherlands.

Classifications MeSH